Trial Profile
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 and 250 mg/Day) as Treatment for Adults With Excessive Sleepiness Associated With Narcolepsy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Jul 2013
Price :
$35
*
At a glance
- Drugs Armodafinil (Primary)
- Indications Narcolepsy
- Focus Registrational; Therapeutic Use
- Sponsors Cephalon
- 01 Feb 2010 New trial record